Tanespimycin
- Generic Name
- Tanespimycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H43N3O8
- CAS Number
- 75747-14-7
- Unique Ingredient Identifier
- 4GY0AVT3L4
- Background
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
- Indication
Investigated for use/treatment in leukemia (myeloid) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00118248
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00117988
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
- Conditions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 25
- Registration Number
- NCT00104897
- Locations
- 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00103272
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
- Conditions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00100997
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00098423
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00098488
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT00096109
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAIDS-related Peripheral/Systemic LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00096005
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00093405
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.